The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.
Transcript (slightly modified)
How do you predict the COTA data analysis platform will shape the future of oncology reform?
We’re in an era where we’re moving toward value-based programs, as opposed to volume-based, and part of the idea of value is to divide the outcomes by the cost. Well, in order to do that, you have to understand what you’re actually seeing, group them properly, and then understand the costs. Most oncologists couldn’t tell you how many patients they see with breast cancer, no less how many patients have HER2/neu breast cancer or stage IV breast cancer. That’s not easily accessible in the electronic health records.
So what COTA has done is try to organize the patients in a way that makes oncologic sense, so that we can then give that information back to the insurance carriers, and to the practices, and even make it available to the public. Once that data’s out there, we can then do big data analytics to then drive the value equation and help with payment reform.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias
July 30th 2025Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.
Read More